Lykos Therapeutics (formerly MAPS PBC)
Brooke Balliett is the Founder, CEO, and Clinical Director at California Center for Psychedelic Therapy. Additionally, Brooke works as a Psilocybin Therapist and Clinical Mentor at COMPASS Pathways. At Lykos Therapeutics, formerly MAPS PBC, Brooke serves as Co-Primary Investigator & Lead Therapist for clinical trials studying MDMA-Assisted Therapy for PTSD. Brook also holds roles at Zendo Project, Hollygrove, Adriana Anaya, PsyD, Children's Hospital Los Angeles (CHLA), UNM Hospitals, and Abt Associates where she has gained experience in a variety of therapeutic and clinical research roles. Educationally, Brooke holds a Doctorate of Psychology in Clinical Psychology from The Chicago School, a Master of Arts in Mental Health Counseling from Southwestern College, and a Bachelor's degree in Developmental Psychology from Mills College.
Lykos Therapeutics (formerly MAPS PBC)
At Lykos Therapeutics, our mission is to transform the way mental health is treated. We aspire to challenge the status quo through the development of novel therapies and therapeutic approaches to treat mental health conditions. With 30+ years of experience researching psychedelic-assisted therapies, we remain focused on following rigorous science from which we can develop and commercialize novel treatment options. Founded in 2014 by the non-profit Multidisciplinary Association for Psychedelic Studies (“MAPS”), we are a for-profit public benefit corporation (“PBC”). As a PBC, we consider the impact of our decisions on society just as we think about financial implications. Everything we do is looked at through a public benefit lens. To learn more, visit us at www.lykospbc.com.